Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 705564 (Double-blind, Randomised, Placebo-controlled, Parallel-group Design) and Evaluation of Midazolam Interaction (Nested, Open, Fixed-sequence, Intra-individual Comparison) in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2017
At a glance
- Drugs BI 705564 (Primary) ; Midazolam
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 20 Nov 2017 Status changed from not yet recruiting to recruiting.
- 14 Nov 2017 Planned initiation date changed from 13 Nov 2017 to 15 Nov 2017.
- 01 Nov 2017 New trial record